EMR Emerson Electric
Good automation franchise, but at $166 the price assumes much more than durable mid-single-digit growth.
The story
Emerson is now a mostly pure-play automation franchise: process control systems, valves and measurement, test and measurement (NI), and industrial software (AspenTech). It has a large installed base and recurring software and service revenue, so it is a mature business that can grow modestly. The low reported sales-to-capital (0.55) comes from acquisition goodwill and says little about what new growth will cost. GAAP margins are held down by amortization of acquired intangibles, so they understate cash economics.
I raised target margin from 20% to 24% (20% relative). The TTM margin of 20.2% has already passed my old target, and acquired-intangible amortization of about 5-6% of revenue weighs on GAAP margins without reflecting how the business runs. I raised sales-to-capital from 1.4 to 2.0 because capex is about 2.4% of revenue, well below D&A, and the business is shifting toward software, so growth needs little new capital. I extended the horizon from 8 to 9 years. All three moves narrow a market gap that is still large on a heavily covered name; growth, terminal growth and beta stay unchanged.
Value drivers
| Revenue growth (Y1) | 5.0% |
| Terminal growth | 2.8% |
| Forecast horizon | 9y |
| Target operating margin | 24.0% |
| Years to target margin | 4 |
| Sales-to-capital | 2.00 |
| Beta | 1.05 |
| Failure probability | 0.5% |
| Cost of capital (WACC) | 9.2% |
| Terminal WACC | 9.0% |
Valuation bridge
| PV of explicit FCFF | 20.86B |
| PV of terminal value | 24.33B |
| Equity value | 33.43B |
| ÷ shares → per share | $59.93 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 19.23B | 5.0% | 21.1% | 3.10B | 457.90M | 2.64B | 2.42B |
| 2 | 20.14B | 4.7% | 22.1% | 3.39B | 453.75M | 2.94B | 2.46B |
| 3 | 21.03B | 4.4% | 23.0% | 3.70B | 446.84M | 3.25B | 2.49B |
| 4 | 21.91B | 4.2% | 24.0% | 4.01B | 437.09M | 3.57B | 2.51B |
| 5 | 22.76B | 3.9% | 24.0% | 4.17B | 424.45M | 3.74B | 2.41B |
| 6 | 23.57B | 3.6% | 24.0% | 4.32B | 408.90M | 3.91B | 2.30B |
| 7 | 24.35B | 3.3% | 24.0% | 4.46B | 390.44M | 4.07B | 2.19B |
| 8 | 25.09B | 3.0% | 24.0% | 4.59B | 369.13M | 4.22B | 2.09B |
| 9 | 25.78B | 2.8% | 24.0% | 4.72B | 345.03M | 4.38B | 1.98B |
Key risks
- Process-industry capex slows (chemicals, energy, discrete/test end markets), hitting orders
- Integrating AspenTech and NI dilutes returns, or the premium paid erodes value
- Leverage (about $11.6B net debt) limits flexibility if margins fall back toward 13-18%
Catalysts
- Sustained 25%+ adjusted margins and software ARR growth that confirm the reshaped portfolio
- Order recovery in test and measurement plus LNG, power and life-sciences project wins